Alexiou C, Kau R J, Luppa P, Arnold W
Department of Otorhinolaryngology, Head and Neck Surgery, Klinikum rechts der Isar, Technical University of Munich, Germany.
Arch Otolaryngol Head Neck Surg. 1998 Nov;124(11):1260-4. doi: 10.1001/archotol.124.11.1260.
To describe patients who developed allergic reactions (ie, erythema on their face and body, itching, flushing, drop in blood pressure, respiratory distress, and cold sweats) immediately after intravenous injection of prednisolone hemisuccinate (SoluDecortin H, E Merck, Darmstadt, Germany).
Academic medical center.
Three of 4 patients had a positive reaction to an intracutaneous test with prednisolone hemisuccinate (SoluDecortin H) but no reaction to the additive sodium succinate. The results of the prick test were negative for all patients. Although no specific IgE antibodies were detected in the serum of these patients, allergic reaction was noted in 3 cases, since standardized techniques to detect antibodies in the serum for hydrocortisone acetate (ie, prednisolone) are lacking. One female patient had a cross-reaction to prednisolone and dexamethasone (Fortecortin, E Merck, Darmstadt, Germany). A renewed application of prednisolone hemisuccinate was well tolerated by all patients when histamine1 and histamine2 receptors were blocked with the use of cimetidine hydrochloride, 200 mg twice per day (1-0-1 ampules, Tagamet, SmithKline Beecham Pharmaceuticals, Philadelphia, Pa) and dimethindene maleate, 4 mg twice per day (1-0-1 ampules, Fenistil, Novartis, Munich, Germany); calcium was given for membrane stabilization.
Allergic reactions to glucocorticoid therapy are only occasionally mentioned in the literature. These reactions appear more often when glucocorticoids are applied topically and may lead to dangerous complications in patients if administered systemically. Therefore, when allergic reactions result from glucocorticoid therapy, (immediate-type reactions should be suspect), consider corticosteroid allergy as a differential diagnosis.
描述静脉注射半琥珀酸泼尼松龙(SoluDecortin H,德国达姆施塔特默克公司)后立即出现过敏反应(即面部和身体红斑、瘙痒、潮红、血压下降、呼吸窘迫和冷汗)的患者。
学术医疗中心。
4例患者中有3例对皮内注射半琥珀酸泼尼松龙(SoluDecortin H)呈阳性反应,但对添加剂琥珀酸钠无反应。所有患者的点刺试验结果均为阴性。尽管在这些患者的血清中未检测到特异性IgE抗体,但由于缺乏检测醋酸氢化可的松(即泼尼松龙)血清抗体的标准化技术,仍有3例出现过敏反应。一名女性患者对泼尼松龙和地塞米松(Fortecortin,德国达姆施塔特默克公司)有交叉反应。当使用盐酸西咪替丁(每天两次,每次200毫克,1 - 0 - 1安瓿,泰胃美,史克必成制药公司,宾夕法尼亚州费城)和马来酸氯苯那敏(每天两次,每次4毫克,1 - 0 - 1安瓿,肤轻松,诺华公司,慕尼黑,德国)阻断组胺1和组胺2受体,并给予钙剂稳定细胞膜时,所有患者再次应用半琥珀酸泼尼松龙均耐受性良好。
糖皮质激素治疗的过敏反应在文献中仅偶尔被提及。这些反应在局部应用糖皮质激素时更常出现,如果全身给药,可能会导致患者出现危险的并发症。因此,当糖皮质激素治疗引起过敏反应时(应怀疑是速发型反应),应考虑将皮质类固醇过敏作为鉴别诊断。